Autoimmune Haemolytic Anaemia clinical trials

Explore recruiting autoimmune haemolytic anaemia clinical trials.

Recruiting autoimmune haemolytic anaemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Autoimmune Haemolytic Anaemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An open-label, long-term, safety and tolerability study of SAR445088 in participants with cold agglutinin disease previously treated with SAR445088 or never treated with SAR445088

Germany, Netherlands, Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

A multicenter, open-label, Phase IIb study to evaluate the efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia (LUMINA 2)

Italy, Spain, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 3, multicenter, randomized, double-blind, placebo- controlled, parallel-group study with an open-label period and long-term extension to assess the efficacy and safety of rilzabrutinib in participants with warm autoimmune hemolytic anemia (wAIHA)

Netherlands, Greece, Sweden, Spain, Hungary, Czechia +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 3, randomized, double-blind, study to assess efficacy and safety of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treatment (VAYHIA)

Germany, Hungary, Italy, Romania, Spain, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Autoimmune Haemolytic Anaemia trials by city

Autoimmune Haemolytic Anaemia in Toronto Autoimmune Haemolytic Anaemia in Vancouver Autoimmune Haemolytic Anaemia in Montreal Autoimmune Haemolytic Anaemia in Calgary Autoimmune Haemolytic Anaemia in Edmonton Autoimmune Haemolytic Anaemia in Ottawa Autoimmune Haemolytic Anaemia in Winnipeg Autoimmune Haemolytic Anaemia in Quebec City Autoimmune Haemolytic Anaemia in Hamilton Autoimmune Haemolytic Anaemia in Kitchener Autoimmune Haemolytic Anaemia in London Autoimmune Haemolytic Anaemia in Halifax Autoimmune Haemolytic Anaemia in New York Autoimmune Haemolytic Anaemia in Los Angeles Autoimmune Haemolytic Anaemia in Chicago Autoimmune Haemolytic Anaemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease